STOCKHOLM, Sweden--(BUSINESS WIRE)--Regulatory News:
The pharmaceutical company GlaxoSmithKline has signed an exclusive worldwide collaboration agreement with Meda’s (STO:MEDAA) partner Valeant Pharmaceuticals for the Retigabine substance. Meda is entitled to receive significant royalties and certain milestone payments.
